Nivolumab-induced tumour-like gastritis:A case report  

作　　者：Elena Cijauskaite Edita Kazenaite Sandra Strainiene Goda Sadauskaite Benediktas Kurlinkus 

机构地区：[1]Faculty of Medicine,Vilnius University,Vilnius 01513,Lithuania [2]Clinic of Gastroenterology,Nephrourology and Surgery,Institute of Clinical Medicine,Faculty of Medicine,Vilnius University,Vilnius 01513,Lithuania [3]Vilnius University Hospital Santaros Clinics,Center of Hepatology,Gastroenterology and Dietology,Vilnius 08661,Lithuania [4]Department of Internal Medicine and Surgery,Antakalnis Clinic,Vilnius 10207,Lithuania

出　　处：《World Journal of Clinical Cases》2023年第18期4350-4359,共10页世界临床病例杂志

摘　　要：BACKGROUND Immune checkpoint inhibitors are one of the modern treatment methods for advanced malignancies.However,this group of medications is also associated with various immune-related adverse events,such as colitis or pneumonitis.Immune checkpoint inhibitor-induced gastritis is a less common adverse event.CASE SUMMARY We describe a 64-year-old woman presenting with diarrhea,nausea,and discomfort in the upper abdominal region.The patient had a history of metastatic lung cancer,which was treated with nivolumab.During the first endoscopy,an infiltrating gastric tumour was suspected.Later,based on endoscopic,histological and radiological findings,nivolumab-induced gastritis was diagnosed.The patient was successfully treated with three courses of omeprazole.CONCLUSION As a consequence of the increased use of immune checkpoint inhibitors,a growing number of reported immune-related adverse events could be expected.The diagnosis of immune checkpoint inhibitor-induced gastritis should be considered when assessing a patient treated with nivolumab with upper gastrointestinal distress.

关 键 词：Nivolumab Immune checkpoint inhibitors Tumour-like gastritis Proton pump inhibitors Case report 

分 类 号：R969[医药卫生—药理学]